Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$648 Hold
3
﹤0.01% 1089
2026
Q1
$550 Hold
3
﹤0.01% 1095
2025
Q4
$528 Hold
3
﹤0.01% 1056
2025
Q3
$420 Hold
3
﹤0.01% 1059
2025
Q2
$377 Sell
3
-2
-40% -$249 ﹤0.01% 1066
2025
Q1
$684 Sell
5
-183
-97% -$26.2K ﹤0.01% 1031
2024
Q4
$28.7K Buy
188
+186
+9,300% +$31.4K ﹤0.01% 706
2024
Q3
$389 Buy
+2
New +$418 ﹤0.01% 1066
2024
Q1
Sell
-236
Closed -$61.6K 989
2023
Q4
$61.6K Sell
236
-37
-14% -$9.09K 0.01% 473
2023
Q3
$70.2K Sell
273
-168
-38% -$44.9K 0.02% 416
2023
Q2
$126K Buy
441
+200
+83% +$59.5K 0.03% 303
2023
Q1
$66.3K Hold
241
0.02% 415
2022
Q4
$66.5K Buy
+241
New +$68.1K 0.02% 392

Other funds holding BIIB

Colonial Trust's BIIB Position: Q2 2026 in Review

Colonial Trust held its Biogen (BIIB) position steady in Q2 2026 at 3 shares worth $648. The position accounts for ﹤0.01% of the portfolio, ranked #1089.

Colonial Trust first reported a position in BIIB in Q4 2022 and has held it in 13 quarters since. The position peaked at $126K in Q2 2023. 1,043 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

  • Colonial Trust held 3 shares of Biogen worth $648 as of Q2 2026.
  • Colonial Trust left its Biogen share count unchanged in Q2 2026.
  • Biogen made up ﹤0.01% of Colonial Trust's portfolio in Q2 2026, its #1089 holding.
  • Colonial Trust first reported a position in Biogen in Q4 2022 and has held it in 13 quarters since.
  • Colonial Trust's Biogen position peaked at $126K in Q2 2023.
  • 1,043 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Colonial Trust's 13F filing for Q2 2026, filed 11 Aug 2026.